BioCentury | Sep 29, 2014
Company News

Epirus, Livzon, Joincare deal

...Epirus Biopharmaceuticals partnered with Livzon Mabpharm Inc. to develop, manufacture and commercialize up to five biosimilar antibodies in...
BioCentury | Sep 26, 2014
Company News

Epirus, Livzon in Asian biosimilar deal

...Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) partnered with Livzon Mabpharm Inc. (Zhuhai City, China) to develop, manufacture and commercialize up...
BioCentury | Apr 21, 2014
Finance

European beachhead

...cash. The merger is slated to close this summer. Epirus' B round was led by Livzon Mabpharm Inc....
BioCentury | Apr 16, 2014
Top Story

Epirus raises $36 million, to reverse-merge

...is advising Zalicus, which was up $0.32 (31%) to $1.35 on Wednesday. Chinese biologics company Livzon Mabpharm Inc....
Items per page:
1 - 4 of 4
BioCentury | Sep 29, 2014
Company News

Epirus, Livzon, Joincare deal

...Epirus Biopharmaceuticals partnered with Livzon Mabpharm Inc. to develop, manufacture and commercialize up to five biosimilar antibodies in...
BioCentury | Sep 26, 2014
Company News

Epirus, Livzon in Asian biosimilar deal

...Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) partnered with Livzon Mabpharm Inc. (Zhuhai City, China) to develop, manufacture and commercialize up...
BioCentury | Apr 21, 2014
Finance

European beachhead

...cash. The merger is slated to close this summer. Epirus' B round was led by Livzon Mabpharm Inc....
BioCentury | Apr 16, 2014
Top Story

Epirus raises $36 million, to reverse-merge

...is advising Zalicus, which was up $0.32 (31%) to $1.35 on Wednesday. Chinese biologics company Livzon Mabpharm Inc....
Items per page:
1 - 4 of 4